Pulmonary Arterial Hypertension Induces a Metabolic and Inflammatory Hepatopathy

This study utilizes single-nucleus RNA sequencing to define the unique metabolic and inflammatory hepatopathy in pulmonary arterial hypertension, revealing a distinct Warburg-like phenotype, impaired endothelial barrier signaling, and activated hepatic stellate cells that correlate with disease severity.

The Gist

Imagine your body is a bustling city. The heart is the central power plant, pumping energy (blood) to every neighborhood. In a condition called Pulmonary Arterial Hypertension (PAH), the pipes leading away from the power plant get clogged and stiff. This forces the power plant (the right side of the heart) to work overtime until it eventually breaks down. This is called Right Ventricular Failure.

For a long time, doctors knew that when the heart failed, the liver (the city's recycling and chemical processing plant) would get sick too. But they didn't know why or how the liver was getting sick. Was it just because the water (blood) was backing up like a flooded basement? Or was the liver's own machinery breaking down?

This paper is like a high-tech detective story where the researchers used a "molecular microscope" (single-nucleus RNA sequencing) to look at the individual workers inside the liver of PAH patients. They compared these workers to those in two other types of sick livers: one caused by a bad diet (NASH) and one caused by a different kind of blood backup (FALD).

Here is what they found, translated into everyday language:

1. The Liver Workers Got Confused and Changed Jobs

The researchers looked at four main types of liver workers:

• Hepatocytes: The main factory workers who process food and drugs.
• Endothelial Cells: The security guards lining the blood vessels.
• Stellate Cells: The construction crew that fixes damage (but can cause scarring if they work too hard).
• Macrophages: The janitors who clean up trash and fight infection.

The Big Discovery: In PAH, these workers didn't just get "flooded"; they completely rewired their internal engines.

2. The Factory Workers (Hepatocytes) Switched to "Emergency Mode"

Normally, liver cells run on a clean, efficient fuel called "oxidative phosphorylation" (like a hybrid car).

• In PAH: The factory workers switched to a dirty, inefficient, but fast-burning fuel called "glycolysis" (like a gas-guzzling race car). This is called the Warburg effect. It's like the factory is running on emergency generators because the main power line is shaky.
• The Result: They stopped processing fats and drugs properly. This explains why PAH patients often have trouble metabolizing medications and why their blood chemistry gets messy.
• The Difference: In the "bad diet" liver (NASH), the workers were over-working on fat processing. In the "flooded" liver (FALD), they were just slowing down. PAH was unique: they were frantically switching to emergency fuel.

3. The Security Guards (Endothelial Cells) Lost Their Grip

The cells lining the blood vessels are supposed to hold hands tightly to keep blood inside the pipes.

• In PAH: These guards started loosening their grip. They stopped holding on to each other (adhesion signaling went down).
• The Metaphor: Imagine a chain-link fence where the links start to rust and fall apart. This makes the vessel walls leaky and weak, which might be why the liver gets damaged even more.

4. The Construction Crew (Stellate Cells) Went into Overdrive

These cells are supposed to fix small scratches.

• In PAH: They got a signal from a "stress sensor" called Piezo1 (think of it as a pressure gauge on a pipe). Because the blood pressure in the liver was high, these sensors screamed "DANGER!"
• The Chain Reaction: This stress signal told the construction crew to start building massive amounts of scar tissue (fibrosis) around the central veins. They also started shouting inflammatory messages (releasing a chemical called IL-6) that confused the factory workers, making them switch to that emergency fuel mode.
• The Key Finding: The more stressed these construction workers were, the sicker the patient's heart and lungs were.

5. The Janitors (Macrophages) Got Agitated

The cleanup crew in PAH livers started shouting louder (increased complement signaling) but stopped listening to the "calm down" orders (reduced JAK-STAT signaling). They were ready to fight, but they weren't very good at cleaning up the dead cells, which slows down healing.

The "Aha!" Moment: It's a Chain Reaction

The authors propose a fascinating theory on how this all happens:

1. High Pressure: The failing heart pushes blood back into the liver, creating high pressure.
2. The Sensor: The construction crew (Stellate cells) has a pressure sensor (Piezo1) that feels this stress.
3. The Alarm: The sensor triggers a stress response (HIF-1) and a shout (IL-6).
4. The Contagion: This shout travels to the factory workers (Hepatocytes), forcing them to switch to that inefficient emergency fuel.
5. The Result: The liver becomes a factory running on the wrong fuel, leaking blood vessels, and covered in scar tissue.

Why Does This Matter?

Before this study, we thought the liver in PAH was just a passive victim of a backed-up heart. Now we know the liver is an active participant in the disease. It's not just getting wet; it's changing its entire operating system.

The Takeaway: If we can stop the construction crew from panicking, or if we can help the factory workers switch back to clean fuel, we might be able to protect the liver and, surprisingly, help the heart and lungs too. It turns out, fixing the liver might be a new way to treat the heart disease itself.

Technical Summary

1. Problem Statement

Right ventricular failure (RVF) is the primary cause of mortality in Pulmonary Arterial Hypertension (PAH). While RVF leads to widespread end-organ dysfunction, including liver impairment, the specific cellular and molecular mechanisms driving PAH-associated hepatopathy remain undefined.

• Clinical Context: Liver dysfunction in PAH (elevated enzymes, fibrosis, stiffness) is a robust predictor of poor outcomes.
• Knowledge Gap: It is unclear whether PAH liver disease is solely a result of chronic venous stasis (congestion) or if systemic metabolic derangements play a distinct role. Furthermore, there is a lack of cell-specific resolution regarding how PAH affects human liver tissue compared to other liver diseases.
• Comparative Need: A direct comparison between PAH hepatopathy, Non-Alcoholic Steatohepatitis (NASH, a metabolically driven disease), and Fontan-associated liver disease (FALD, a venous stasis-driven disease) is missing to delineate unique pathogenic signatures.

2. Methodology

The study employed a multi-omics approach combining single-nucleus RNA sequencing (snRNA-seq), histology, and proteomics.

• Sample Collection:
  • PAH Cohort: Autopsy-derived liver tissue from 5 PAH patients (confirmed cause of death) and 4 non-PAH controls.
  • Comparative Datasets: Publicly available snRNA-seq data from NASH (4 patients, 3 controls) and FALD (4 patients, 2 controls) were re-analyzed using a unified pipeline.
• Single-Nucleus RNA Sequencing (snRNA-seq):
  • Nuclei were isolated using a modified low-volume dissociation protocol and processed via 10x Genomics.
  • Data Processing: Standard Seurat v5 workflow (normalization, scaling, dimensionality reduction, clustering). Doublet removal and cell type annotation were performed using conserved marker genes and the Human Protein Atlas.
  • Analysis: Differential gene expression (DEG) was performed using DESeq2 (pseudobulked for PAH) and Wilcoxon rank-sum tests (for NASH/FALD). Pathway enrichment was conducted via ShinyGO.
• Cell-Cell Communication: CellChat v2 was used to predict ligand-receptor interactions and signaling strength between cell types.
• Validation:
  • Histology: Masson Trichrome staining for fibrosis quantification; Immunohistochemistry (IHC) for $\alpha$-smooth muscle actin ($\alpha$-SMA) and CD206 (macrophages).
  • Proteomics: Mitochondrial-enriched fractions from a subset of human liver samples were analyzed to validate transcriptomic metabolic findings.
  • Correlation Analysis: HIF-1 pathway module scores were correlated with clinical hemodynamic markers (mPAP, RAP, PVR, etc.).

3. Key Contributions

• First Cell-Specific Atlas: Generated the first single-cell transcriptomic atlas of human PAH hepatopathy, identifying distinct alterations in hepatocytes, endothelial cells (ECs), hepatic stellate cells (HSCs), and macrophages.
• Disease Differentiation: Defined molecular signatures that distinguish PAH liver disease from NASH (metabolic) and FALD (venous stasis), proving that PAH hepatopathy is a unique entity with mixed metabolic and inflammatory features.
• Mechanistic Hypothesis: Proposed a novel mechanistic model linking hemodynamic stress to liver metabolic reprogramming via the Piezo1-HIF-1-IL-6 axis.

4. Key Results

A. Cellular Composition Changes

• PAH Livers: Showed increased relative abundance of hepatocytes, ECs, plasma cells, and macrophages, but a significant reduction in HSCs, lymphocytes, and cholangiocytes compared to controls.
• Comparison: NASH and FALD showed different patterns of cellular abundance shifts, highlighting the unique cellular landscape of PAH.

B. Cell-Type Specific Alterations

1. Hepatocytes (Metabolic Reprogramming):

   • PAH: Adopted a Warburg-like phenotype (aerobic glycolysis) with preserved oxidative phosphorylation but suppressed gluconeogenesis and fatty acid metabolism. Cytochrome P450 activity was reduced.
   • Contrast: NASH hepatocytes showed hypermetabolism (increased glycolysis, FA metabolism, and OXPHOS), while FALD hepatocytes suppressed OXPHOS without increasing glycolysis.
   • Adhesion: PAH hepatocytes showed suppressed cell adhesion and barrier signaling, unlike FALD which showed increased structural remodeling.

2. Endothelial Cells (ECs):

   • PAH: Exhibited Warburg-like metabolism (high glycolysis, low OXPHOS) and impaired barrier function (reduced cadherin and protease-activated receptor signaling).
   • Contrast: FALD ECs showed structural/angiogenic remodeling, while NASH ECs showed dysregulated vascular homeostasis.

3. Hepatic Stellate Cells (HSCs):

   • PAH: Enriched for PI3K-Akt and HIF-1 signaling. Unlike NASH and FALD, PAH HSCs did not co-activate TGF-$\beta$.
   • Fibrosis: Despite reduced TGF-$\beta$, PAH livers showed significant perivascular fibrosis and increased $\alpha$-SMA positive activated HSCs.
   • Correlation: HSC HIF-1 activation strongly correlated with PAH severity (mPAP, PVR) and perivascular fibrosis.

4. Macrophages:

   • PAH: Upregulated complement signaling but suppressed JAK-STAT activity. This contrasts with FALD (upregulated JAK-STAT) and NASH (upregulated complement).
   • Signaling: PAH macrophages showed reduced cell-cell communication but heightened immune activation.

C. Systemic Implications & Mechanistic Model

• Vasoactive Dysregulation: PAH livers showed upregulation of pro-proliferative genes (FLT1, GDF15) and downregulation of vasodilators (GDF2/BMP9).
• Inflammation: IL-6 expression was significantly elevated in PAH HSCs, macrophages, and hepatocytes.
• Metabolic Suppression: Ketone metabolism was significantly suppressed in PAH hepatocytes.
• Proposed Mechanism (Piezo1-HIF-1-IL-6):
  1. Hemodynamic stress (congestion/pressure) activates Piezo1 mechanosensitive channels in HSCs.
  2. Piezo1 activation triggers HIF-1 signaling and IL-6 secretion.
  3. IL-6 acts in a paracrine manner on hepatocytes to drive HIF-1 activation, resulting in the Warburg-like metabolic shift and suppression of ketogenesis.

5. Significance

• Pathophysiological Insight: The study redefines PAH hepatopathy not merely as passive congestion (FALD-like) but as an active, metabolically reprogrammed inflammatory state distinct from NASH.
• Therapeutic Targets:
  • HIF-1 Modulation: Targeting HIF-1 signaling in hepatocytes could restore ketone production and drug metabolism (Cytochrome P450).
  • IL-6/Piezo1: Blocking the Piezo1-IL-6 axis in HSCs could mitigate fibrosis and metabolic derangement.
  • Ketone Supplementation: The finding of suppressed ketogenesis suggests a potential therapeutic avenue for RVF patients who fail to mount compensatory ketosis.
• Biomarkers: HIF-1 activation in HSCs and IL-6 levels are identified as potential biomarkers correlating with RVF severity.

In conclusion, this paper provides a comprehensive molecular map of PAH-induced liver disease, revealing that hemodynamic stress triggers a specific metabolic and inflammatory cascade involving HSCs and hepatocytes that exacerbates systemic disease and right ventricular failure.